Aims: Most programs specializing in the treatment of first-episode psychosis in the United States focus on schizophrenia. However, many early psychosis patients do not fit into this diagnostic category. Here we describe McLean OnTrack, an intensive outpatient treatment program that accepts all comers with firstepisode psychosis.
INTRODUCTION
The initial years following a first episode of psychosis are a critical period for intervention, when the greatest impact can be made to change the trajectory of illness and reduce the risk of long-term disability. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] In the United States, much of the effort to date on treating early stages of psychotic disorders has focused on primary psychotic disorders such as schizophrenia (e.g., 11, 12) . Schizophrenia and bipolar disorder are usually treated in different specialty clinics that are staffed by different sets of clinicians, and most 'first-episode' programs focus primarily, or even solely, on schizophrenia. Patients who do not fit neatly into the schizophrenia category might be turned away from such first-episode programs. And yet, most patients present with an unclear clinical picture during the initial episode, with varying degrees of mood and psychosis symptoms. Moreover, diagnostic shifts, whether due to changes in the illness course or misclassification, are not uncommon. 13, 14 First-episode patients may be diagnosed with affective psychosis (bipolar disorder or major depressive disorder with psychotic features) early in illness and diagnosed with schizophrenia spectrum disorders later. Similarly, patients initially suspected to have schizophrenia may later be diagnosed with other disorders. Others present with a mixed picture consistent neither with schizophrenia spectrum disorders nor with affective psychosis. A common assumption is that full inter-episode recovery and less functional disability occur in affective disorders compared with schizophrenia. However, schizophrenia and affective psychotic disorders are likely not discrete entities but disorders that occur on a continuum. 15 Although outcomes following a first episode of affective psychosis might be more variable than in schizophrenia, a growing body of evidence suggests that the clinical course of bipolar disorder is often cumulative and potentially deteriorating, 16, 17 not unlike that of schizophrenia. In particular, a larger number of episodes is associated with poorer social adjustment, greater hospitalizations, decreased treatment response, higher suicide rates, more substance abuse, greater cognitive impairments, progressive structural brain changes and reduced quality of life. 18, 19 Early intervention after a first episode of mania is necessary to modify these risks and improve the trajectory of illness. [20] [21] [22] [23] These studies suggest that all patients with first-episode psychosis, not just those with schizophrenia, stand to benefit from early intervention. [1] [2] [3] Moreover, the frequency of diagnostic shifts suggests that early intervention programs may serve patients more effectively by tailoring programs to the presence or absence of symptom clusters, which are likely to evolve over the course of the illness, rather than on diagnosis per se.
Here, we describe a transdiagnostic program for early intervention in psychotic illness, and report on our experiences in working with diagnostic heterogeneity and shifts over the life of the program. Our goals are to provide a brief overview of the clinic's treatment philosophy and services, report baseline characteristics of our clinic sample and determine the rates of change between referral diagnoses and active diagnoses, which if elevated would lend further support to the transdiagnostic approach to early intervention in our patients.
The Because patients in OnTrack are heterogeneous and have different needs, the combination and intensity of services delivered depends on individual circumstances. We offer evidence-based pharmacological treatment, individual psychotherapy, group psychotherapy, community-based care and family support programs. Because symptomatic recovery is not strongly correlated with functional recovery and medications for psychosis symptoms may not necessarily enhance functioning, 24 we do not aim for complete eradication of symptoms and treat using the lowest effective doses of medications. To engage young people in the process of creating meaning in their lives, we use multiple psychotherapeutic approaches, including less structured activities such as nature walks, expressive art therapies 25 and self-narrative oriented psychotherapy, 26 as well as manualized psychotherapies such as cognitive behavioural therapy, 27 personal therapy, 28 individual resiliency training 12 and interpersonal and social rhythm therapy. 29 Although many of these psychotherapies were originally designed for patients with schizophrenia, studies suggest that early psychosocial intervention is also critical for improved functional recovery in first-episode mania, 30 and we are adapting many of these treatments to address varying needs along the full spectrum of psychosis. For individuals with difficulty participating in traditional outpatient settings, a community-based social worker meets with patients and families in their homes or at school, and also assists with activities such as applying for jobs or navigating meetings with school administrators. Finally, we support caregivers and incorporate them as an essential part McLean OnTrack of the treatment team, providing guidance, support and psychoeducation, both individually and in a group setting.
METHODS
We report on clinical and demographic characteristics of patients enrolled in OnTrack during the program's first 2.5 years. We provide data on all patients seen in the clinic, as well as those actively receiving treatment in OnTrack as of 21 January 2015. We considered a patient to be active if they received any component of treatment at OnTrack within the prior 3 months.
We also explore clinical and demographic characteristics by category of psychosis (affective psychosis, primary psychotic disorder, psychotic disorder not otherwise specified (NOS) and no psychosis), providing age, duration of treatment in the program, referral source, hospitalization history, history of pre-morbid substance use disorders (SUD) and premorbid functional status (whether a patient was working or attending school prior to program entry). Patients were categorized on the basis of their current diagnoses as of 21 January 2015, extracted from OnTrack medical records. Lastly, we report on the initial referral diagnoses and the evolution of provisional diagnoses during treatment. We obtained referral diagnoses from medical records and intake paperwork completed by referring clinicians and/or family members. Table 1 provides baseline demographic characteristics of OnTrack patients. The 'all-enrolled' and 'active-only' groups are similar in diagnostic composition (Fig. 1) . Table 2 provides demographic and clinical characteristics by category of psychosis. The majority of patients are male and affective psychosis makes up the largest proportion of patients. The majority of patients (64.8%) have a comorbid SUD at intake, with cannabis being the most common abused substance (Fig. 2) . More than half of our patients (60.4%) were enrolled in school when they experienced their first episode. Most patients were referred from hospitals and had an average of 1.6 hospitalizations prior to program entry. The overall retention rate (measured by the percentage of active patients) in OnTrack is 75.8%, with 80.0% for affective, 86.7% for primary psychosis and 52.6% for psychotic disorder NOS (Fig. 3a) . Among patients who were enrolled in OnTrack but are no longer active (n = 22), 15 (68.2%) dropped out at or before 3 months (early dropouts), whereas seven (31.8%) engaged for 7 or more months before discontinuing treatment (later dropouts). Among the early dropouts, the majority (77.3%) had affective psychosis or psychotic disorder NOS (Fig. 3b) .
RESULTS

Baseline demographic and clinical characteristics
Evaluation of diagnostic change
A total of 50.5% of patients in OnTrack had a change in diagnosis between time of referral and the most recent documented diagnosis. Figure 4 shows the distribution of current diagnoses from each referral diagnosis. Patients referred with bipolar disorder with psychotic features are the most diagnostically stable, with only one patient (4.2%) having changed diagnosis. Diagnoses changed in 68.9% of psychotic disorder NOS referrals, 44.4% of schizophrenia referrals, 50.0% of schizoaffective disorder referrals, 85.7% of psychotic depression referrals and in 100% of the two individuals referred with substanceinduced psychosis.
DISCUSSION
McLean OnTrack is a specialized first-episode psychosis program that takes a dimensional and transdiagnostic approach to early intervention, treating all comers with first-episode psychosis under one roof. A first episode of psychosis is frequently associated with high clinical severity and marked disruption in functioning, and these challenges are not unique to schizophrenia. We tailor our approach to patients' individual needs, with the ultimate goal of helping individuals get back 'on track', regardless of their diagnostic category. Here, we report on baseline clinical and demographic characteristics of OnTrack patients and find that diagnostic heterogeneity is the norm. Only 33% of OnTrack patients have a primary psychotic disorder (i.e. schizophrenia or schizoaffective disorder). A large number of individuals with affective psychosis (44%) and psychotic disorder NOS (19%) comprise the clinic population as well. Our inclusive approach, to treat patients with a variety of psychotic disorders, has by definition resulted in a more heterogeneous patient group than is typically found in first-episode clinics in the United States, and includes patients with bipolar disorder, major depressive disorder and those with symptoms that are atypical or otherwise ill-defined.
We also find that shifts in diagnoses are common. In our sample, diagnoses evolved for 50.5% of patients following entry into our program. This rate is consistent with the overall rate (50.7%) of diagnostic shifts found in a study of first-admission psychosis patients followed for a decade.
14 Although the majority of patients referred with bipolar disorder with psychotic features were diagnostically stable, diagnostic change was otherwise common, suggesting that diagnosis tends to be highly dynamic in the course of early psychosis. The implications of this finding are twofold: first, single-diagnosis specialty clinics that admit based on referral or baseline diagnosis are, in reality, likely treating a heterogeneous group of patients; second, limiting early interventions to only patients who clearly meet diagnostic criteria for schizophrenia early in their illness would miss many individuals who would otherwise benefit from intensive treatment.
Excluding individuals from receiving early intervention on the basis of referral diagnosis presents a missed opportunity to improve patient outcomes, as our data suggest that first-episode psychosis patients, regardless of diagnosis, stand to benefit from early intervention. Specifically, although the affective psychosis group has higher pre-morbid functional status, all categories of psychosis (affective, primary psychotic disorder or psychotic disorder NOS) have similar baseline indices of illness severity, including high rates of prior hospitalizations and SUD, particularly cannabis use disorders. A recent study comparing first-episode patients with and without cannabis misuse at baseline found that baseline cannabis misuse was predictive of poorer social functioning over a 30-month follow-up period. 31 First-episode patients with comorbid SUD have unique needs that may be different from SUD patients without psychosis, and even from SUD patients with chronic psychosis. To address these unique needs, we are working with SUD experts at McLean Hospital to develop a program geared specifically for SUD in first-episode patients, particularly targeting cannabis use disorder.
Furthermore, the retention rate in individuals with psychotic disorder NOS is markedly lower than that in clearly diagnosed affective and primary psychotic disorders, and patients with affective psychosis or psychotic disorder NOS comprised the majority of individuals who dropped out of treatment early. Getting 'buy-in' from patients and families is essential for positive clinical outcomes and optimal use of resources. Our findings suggest that we need to step up efforts to increase patient engagement, and that those efforts should target individuals with affective psychosis or psychotic NOS, psychotic disorder not otherwise specified; SZ, schizophrenia; SZA, schizoaffective disorder; BP, bipolar disorder with psychotic features; MDD, major depressive disorder with psychotic features; SIP, substance-induced psychotic disorder.
disorder NOS as well as those with primary psychotic disorders. Technology and social networking may offer creative solutions that enhance patient autonomy and synergistically complement our clinical services. A study of first-episode patients found that 100% regularly used computers, 92% cellphones/smartphones and 83% gaming consoles, indicating that technology-based platforms for information and treatment delivery may be particularly beneficial for these patients. 32 We are developing a series of animated psychoeducational videos and a suite of mobile apps geared towards reaching the young adult demographic group. In focus groups, patients have expressed interest in using apps and electronic support tools to enhance their care, consistent with previous research. 33 The National Institute of Mental Health's Research Domain Criteria (RDoC) initiative is designed to encourage researchers to find new ways of classifying psychopathology based on dimensions of observable behaviour and neurobiological measures, cutting across traditional diagnoses. 34 Although the RDoC framework was intended primarily for research, it arises directly out of the clinical reality that existing psychiatric nosology is inadequate. McLean OnTrack represents an example of RDoC-consistent principles applied in the real world of clinical treatment. The findings from our OnTrack patient sample mirror the accumulating genetic and neurobiological research into the shared underpinnings of affective and nonaffective psychotic disorders 35, 36 as traditionally defined. Moreover, a transdiagnostic clinical program such as OnTrack provides a natural referral source for translational investigations of the neurobiological and genetic causes of psychosis at the dimensional, rather than categorical, level. Our findings of diagnostic heterogeneity and instability early in illness point to the value of a more inclusive approach, and highlight the need for more availability of research into transdiagnostic early intervention programs that target the whole dimension of first-episode psychosis rather than the narrow category of schizophrenia.
We recognize that the transdiagnostic approach is not without challenges. For example, we observe that the OnTrack psychotherapy group is primarily attended by individuals with affective psychosis. A major challenge in OnTrack is determining how best to deliver care in the face of diagnostic heterogeneity, uncertainty and instability, as well as how to most efficiently and effectively adapt programs to benefit patients who share many but not all illness characteristics. Future directions might include personalized medicine approaches. For example, we have already mentioned the potential role for innovation and technology in reaching transitional age youth. A mobile app that can provide the treatment team with detailed metrics on each individual, derived from both active (i.e. pop-up surveys) and passive (i.e. sensor data such as accelerometer and phone usage) data collection, to generate a personalized phenotype could have major impact in aiding diagnosis and optimizing treatment planning.
Some limitations to our report deserve consideration. First, we present clinical diagnoses as documented in the patients' medical records; diagnoses were not systematically confirmed using a structured interview. On the other hand, our data were extracted from longitudinal medical records and reflect the richness of a real-world clinical setting. Second, although we provide data about the percentage of patients whose diagnoses have changed, we do not present data about when or why this occurred, which could provide insights into mechanism of evolution. In the future, we plan to examine whether such diagnostic changes result from improved recognition of existing symptomatology or from evolution of the illness itself.
To conclude, McLean OnTrack offers integrated, intensive treatment to all comers with first-episode psychosis. We describe our goal to help first-episode patients get back 'on track' regardless of their presumed diagnoses and the development of novel interventions to enhance patient engagement and decision making. In our first-episode patients, diagnostic heterogeneity is the norm and diagnoses frequently change over the early illness course. Baseline indices of illness severity are similar across categories of first-episode psychosis, and suggest the need for early intervention, irrespective of diagnosis. Given these clinical realities, we recommend an inclusive approach that transcends traditional diagnostic boundaries when studying and treating first-episode patients.
